ArticleTransfusion2025
Babesia nucleic acid prevalence among blood donors in southern Québec.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Using blood donor surveillance and clinical case data to shape our understanding of Babesia epidemiology in Manitoba, Canada.Transfusion · 2026Article
- Babesia nucleic acid prevalence among blood donors in southern Québec.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundTick-borne diseases are on the rise in Canada, and southern Québec is considered one of the highest-risk regions for Babesia emergence. Babesia is easily transmissible through blood transfusion and was the most common transfusion-transmitted infection in the United States before the implementation of nucleic acid testing (NAT) in 2020. Babesia NAT is not yet implemented in Canada, and prevalence studies are necessary for risk assessment. Therefore, Héma-Québec performed a new prevalence study in the summer of 2024. STUDY DESIGN AND
methodsWhole blood and platelet donors were sampled between June 1, 2024, and October 31, 2024, in four high-risk administrative regions in southern Québec (i.e., Estrie, Montérégie, Montréal, and Mauricie-Centre-du-Québec). The samples were tested at the American Red Cross with a qualitative Babesia NAT, i.e., the Procleix Babesia assay.
resultsA total of 28,800 donations were collected and tested from four high-risk administrative regions of the province of Quebec. All donations tested negative for Babesia NAT. DISCUSSION: While public health data indicate that Babesia microti is emerging in southern Québec, to date, the risk of acquiring babesiosis through transfusion of blood products remains low. Partnership with public health authorities and clinicians remains essential to keep abreast of the emergence of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.